The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the first and only treatment approved for this rare autoimmune disease in the United States. An estimated 200,000 people in the United States are living with IgG4-RD...
112 N Bayshore Blvd #3 San Mateo, Ca 94401
650-544-0793
jamesfgraham111@gmail.com
Copyright © 2024 botnik. All Rights Reserved
